Research

Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.

Over 10 years, multiple healthy behaviors did not slow the progression of arterial stiffness, a risk factor for coronary artery disease, hypertension, stroke, atrial fibrillation and heart failure.

Birth outcomes including postpartum infection and blood transfusion were similar in women with and without rheumatoid arthritis, and continued use of disease-modifying antirheumatic drugs and biologics is recommended to limit steroid exposure.

Adolescent and young adult oncology patients and caregivers experience psychosocial impairment and financial toxicity at the time of cancer diagnosis, findings that will inform interventions to support patient and caregiver well-being.

Vanderbilt's Clickbusters program is helping to stem alert fatigue associated with the Medical Center's clinical IT system.

A treatment that increases levels of lipid signaling molecules reduced adipose tissue inflammation in obese adults, suggesting this pathway may be a valuable target for modulating fat and systemic inflammation.

Vanderbilt researchers have found that children with a genetic makeup that predicts high blood pressure as adults are more likely to survive congenital heart defect repair surgery.